BIBP 3226 Trifluoroacetate: Unraveling the NPY/NPFF Axis in Cardiac and Neural Research

Introduction

Non-peptide antagonists targeting neuropeptide Y (NPY) and neuropeptide FF (NPFF) receptors have transformed the landscape of neuropharmacological and cardiovascular research. Among these, BIBP 3226 trifluoroacetate (CAS: 1068148-47-9) stands out for its exceptional selectivity and potency as a non-peptide NPY Y1 receptor antagonist and NPFF receptor antagonist. While prior literature has focused on its utility in dissecting anxiety, analgesia, and cardiovascular regulation, recent scientific advances—particularly in the understanding of the adipose-neural axis in cardiac arrhythmias—invite a more integrative and mechanistic exploration of BIBP 3226 trifluoroacetate’s research potential.

The NPY/NPFF System: A Convergence Point for Neural and Cardiac Pathways

The NPY/NPFF system is a fundamental neurochemical axis involved in diverse physiological processes, from emotional regulation to cardiovascular homeostasis. NPY, acting primarily via the Y1 receptor (Y1R), and NPFF, through its distinct FF receptors, orchestrate complex signaling cascades that integrate autonomic, metabolic, and nociceptive inputs. Disruptions in this axis have been implicated in anxiety, pain modulation, and the pathogenesis of cardiovascular disorders.

Recent findings, such as those reported by Fan et al. in their seminal study, have elucidated the centrality of the adipose-neural axis—especially leptin-mediated NPY release and Y1R activation—in epicardial adipose tissue (EAT)-related cardiac arrhythmias. Their stem cell-based coculture model demonstrated that adipocyte-derived leptin activates sympathetic neurons, escalating NPY secretion, which subsequently triggers arrhythmogenic signaling in cardiomyocytes via the Y1 receptor pathway. This discovery not only highlights the multifaceted roles of NPY/NPFF signaling but also underscores the need for precise molecular tools like BIBP 3226 trifluoroacetate to dissect these mechanisms in vitro and in vivo.

Mechanism of Action of BIBP 3226 Trifluoroacetate

Receptor Selectivity and Binding Affinity

BIBP 3226 trifluoroacetate distinguishes itself as a highly selective non-peptide NPY Y1 receptor antagonist, exhibiting a Ki of 1.1 nM for rat NPY Y1, while also antagonizing human NPFF2 (Ki: 79 nM) and rat NPFF (Ki: 108 nM) receptors. This dual antagonism enables researchers to parse the complex interplay between NPY and NPFF signaling with extraordinary precision.

cAMP Signaling Inhibition and Downstream Effects

Mechanistically, BIBP 3226 trifluoroacetate competes with NPFF, effectively preventing NPFF-induced inhibition of forskolin-stimulated cyclic AMP (cAMP) production. Through this action, it disrupts a critical node in the neuropeptide Y receptor pathway and neuropeptide FF receptor pathway, allowing researchers to delineate the downstream effects of cAMP signaling inhibition on cellular excitability, neurotransmitter release, and gene expression.

Physiological Impacts: From Hypothermia to Anti-Opioid Effects

In rodent models, BIBP 3226 trifluoroacetate has been shown to block NPFF-dependent hypothermic and anti-opioid effects, providing a robust tool for investigating the physiological and behavioral roles of the NPY/NPFF system in anxiety research and analgesia mechanism studies.

Integrating BIBP 3226 Trifluoroacetate in Advanced Cardiac Arrhythmia Models

Insights from the Adipose-Neural Axis

The recent work by Fan et al. (2024) has redefined our understanding of cardiac arrhythmogenesis by illuminating the role of the adipose-neural axis and the NPY/Y1R signaling cascade. Their coculture system, consisting of sympathetic neurons, adipocytes, and cardiomyocytes, demonstrated that leptin-driven activation of NPY/Y1R signaling triggers arrhythmias by upregulating the Na⁺/Ca²⁺ exchanger (NCX) and calcium/calmodulin-dependent protein kinase II (CaMKII) activity. Importantly, antagonism of the Y1 receptor partially abrogated these arrhythmic effects, highlighting the translational potential of selective Y1R antagonists.

Experimental Applications of BIBP 3226 Trifluoroacetate

Given its high specificity and potent antagonism, BIBP 3226 trifluoroacetate is uniquely suited for such advanced models. By incorporating BIBP 3226 trifluoroacetate (B7155) into stem cell-based coculture or organoid systems, researchers can interrogate the real-time consequences of NPY/NPFF blockade on cardiac electrophysiology, arrhythmia susceptibility, and downstream calcium signaling. This approach enables not only the validation of mechanistic pathways identified by Fan et al. but also the exploration of novel intervention strategies in cardiovascular regulation research.

Comparative Analysis: Beyond Conventional NPY/NPFF Research Tools

While peptide-based antagonists and genetic knockdown models have traditionally been employed to study the NPY/NPFF system, they present notable limitations, including poor bioavailability, rapid degradation, and off-target effects. As detailed in existing reviews, BIBP 3226 trifluoroacetate's non-peptide structure confers greater stability, superior receptor selectivity, and compatibility with complex in vitro and in vivo systems.

Whereas prior articles have emphasized BIBP 3226 trifluoroacetate as a 'precision tool' for general NPY/NPFF system research in anxiety and analgesia, this article extends the discourse by integrating its role in the context of the adipose-neural axis and cardiovascular pathophysiology—providing a more holistic and translational framework for its application.

Advanced Applications in Translational Neurocardiology

Deciphering the NPY/NPFF Axis in Atrial Fibrillation and Beyond

With the demonstration that increased EAT thickness and elevated leptin/NPY levels are associated with atrial fibrillation (AF), as shown by Fan et al., the NPY/NPFF axis emerges as a promising target for arrhythmia intervention. BIBP 3226 trifluoroacetate facilitates the dissection of Y1R-mediated signaling events underlying AF onset, including modulation of NCX and CaMKII activity. These insights lay the groundwork for the rational design of next-generation anti-arrhythmic therapies that transcend traditional β-adrenergic blockade.

Expanding the Scope: Anxiety and Analgesia Mechanism Studies

Beyond the cardiovascular domain, BIBP 3226 trifluoroacetate remains invaluable for anxiety research and analgesia mechanism study. Its ability to selectively block NPY Y1 and NPFF receptors allows researchers to parse the contributions of these pathways to stress responsiveness, mood regulation, and pain perception—phenomena inextricably linked to cAMP signaling inhibition and neuropeptide receptor cross-talk.

Practical Considerations for Laboratory Use

BIBP 3226 trifluoroacetate is supplied as an off-white solid with a molecular weight of 587.59 and chemical formula C₂₉H₃₂F₃N₅O₅. It dissolves readily at ≥78 mg/mL in DMSO, ≥73.2 mg/mL in ethanol, and ≥12.13 mg/mL in water (with ultrasonic assistance), providing flexibility for diverse assay formats. For optimal activity, solutions should be freshly prepared and stored at -20°C, as long-term storage may compromise stability. Each batch is accompanied by comprehensive quality control data, including HPLC, MS, NMR, and a Certificate of Analysis (COA), ensuring rigorous reproducibility for scientific research use.

Building Upon and Advancing Existing Discourse

Previous analyses, such as the article "BIBP 3226 Trifluoroacetate: Precision Tool for NPY/NPFF S...", have primarily highlighted the compound's role in facilitating selective studies of the neuropeptide Y and FF receptor pathways, with an emphasis on anxiety, analgesia, and cardiovascular regulation in translational settings. In contrast, this article delves deeper into the mechanistic underpinnings of NPY/NPFF signaling within the adipose-neural axis and its direct implications in cardiac arrhythmogenesis, as illuminated by recent stem cell coculture models. By bridging molecular pharmacology with disease modeling, we offer a distinct perspective that not only complements but significantly extends the existing content landscape.

Conclusion and Future Outlook

BIBP 3226 trifluoroacetate stands at the forefront of non-peptide NPY Y1 and NPFF receptor antagonists, enabling unprecedented precision in the investigation of neuropeptide signaling across neural and cardiac contexts. The convergence of advanced coculture models and selective molecular tools—underscored by breakthroughs in understanding the adipose-neural axis—ushers in a new era for NPY/NPFF system research. As the field moves toward integrative models of disease and therapeutic intervention, BIBP 3226 trifluoroacetate will remain an indispensable asset for elucidating the intricate mechanisms governing anxiety, analgesia, and cardiovascular regulation. For more information on experimental protocols and ordering, visit the BIBP 3226 trifluoroacetate product page.